---
document_datetime: 2025-12-02 05:48:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fycompa.html
document_name: fycompa.html
version: success
processing_time: 0.132186
conversion_datetime: 2025-12-27 20:07:39.528034
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fycompa

[RSS](/en/individual-human-medicine.xml/65681)

##### Authorised

This medicine is authorised for use in the European Union

perampanel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fycompa](#news-on)
- [More information on Fycompa](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fycompa is an epilepsy medicine for treating:

- partial seizures (fits starting in one specific part of the brain), including those followed by generalised seizures affecting all of the brain, in patients from 4 years of age;
- primary generalised tonic-clonic seizures (major fits fit affecting most or all of the brain) in patients from 7 years of age when the cause of epilepsy is unknown.

Fycompa must only be used as an 'add-on' therapy to other anti-epileptic medicines. It contains the active substance perampanel.

Expand section

Collapse section

## How is Fycompa used?

Fycompa is taken by mouth once a day at bedtime. Fycompa tablets can be taken with or without food and should not be chewed, crushed or split. Fycompa oral suspension can be taken with or without food and should always be taken in the same way (i.e. always with food or always without food).

For patients above 12 years of age, the recommended dose at the start of treatment is 2 mg per day, and if it is well tolerated the doctor may progressively increase it by increments of 2 mg/day to a maximum dose of 12 mg per day. For younger patients the dose depends on their weight.

Fycompa can only be obtained with a prescription. For more information about using Fycompa, see the package leaflet or contact your doctor or pharmacist.

## How does Fycompa work?

The active substance in Fycompa, perampanel, is an anti-epileptic medicine. Epilepsy is caused by excessive electrical activity in the brain. Although the precise mechanism by which Fycompa works is not fully understood, it is thought to block the action of the neurotransmitter glutamate. Neurotransmitters are naturally-occurring chemicals in the nervous system that allow nerve cells to communicate with each other. Glutamate is the main stimulatory neurotransmitter in nerve cells that can trigger and maintain seizures. Therefore, by blocking glutamate's actions, Fycompa is thought to stop epileptic seizures from occurring.

## What benefits of Fycompa have been shown in studies?

Three main studies involving a total of 1,491 patients aged 12 years and older showed that Fycompa was more effective than placebo (a dummy treatment) in reducing the frequency of partial seizures. In the first study, the percentage of patients who experienced a decrease in seizure frequency of at least 50% was 37.6% for patients taking 8 mg Fycompa and 36.1% for patients taking 12 mg Fycompa, compared with 26.4% of patients taking placebo. In the second study, 33.3% and 33.9% of patients taking 8 mg and 12 mg Fycompa respectively showed a decrease in seizure frequency of at least 50%, compared with 14.7% of patients taking placebo. The third study showed a significant decrease in seizure frequency only in patients taking 4 mg and 8 mg Fycompa but not in patients taking a dose of 2 mg.

A fourth study in 164 patients with generalised epilepsy of unknown cause also showed that Fycompa was more effective than placebo: 47 of 81 patients (58%) given Fycompa had at least a 50% reduction in frequency of seizures, compared with 29 of 81 (36%) of those given the dummy treatment. Supportive evidence from patients treated for up to 2 years suggested that the benefit was maintained with longer treatment and that some patients could benefit from doses up to 12 mg.

Additional data indicate that Fycompa is as effective in younger children as in those above 12 years of age.

## What are the risks associated with Fycompa?

The most common side effects with Fycompa (seen in more than 1 patient in 10) are dizziness and somnolence (sleepiness). For the full list of all side effects and restrictions with Fycompa, see the package leaflet.

## Why is Fycompa authorised in the EU?

Studies showed that Fycompa, taken together with other anti-epileptic medicines, showed a consistent reduction in the frequency of epileptic fits and its side effects are manageable. The European Medicines Agency decided that Fycompa's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fycompa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fycompa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fycompa are continuously monitored. Side effects reported with Fycompa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Fycompa

Fycompa received a marketing authorisation valid throughout the EU on 23 July 2012.

Fycompa : EPAR - Medicine overview

Reference Number: EMA/697784/2020

English (EN) (134.75 KB - PDF)

**First published:** 07/08/2012

**Last updated:** 13/01/2021

[View](/en/documents/overview/fycompa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-539)

български (BG) (159.72 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/bg/documents/overview/fycompa-epar-medicine-overview_bg.pdf)

español (ES) (137.35 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/es/documents/overview/fycompa-epar-medicine-overview_es.pdf)

čeština (CS) (158.97 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/cs/documents/overview/fycompa-epar-medicine-overview_cs.pdf)

dansk (DA) (145.05 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/da/documents/overview/fycompa-epar-medicine-overview_da.pdf)

Deutsch (DE) (139.94 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/de/documents/overview/fycompa-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.32 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/et/documents/overview/fycompa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.58 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/el/documents/overview/fycompa-epar-medicine-overview_el.pdf)

français (FR) (138.35 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/fr/documents/overview/fycompa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (159.07 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/hr/documents/overview/fycompa-epar-medicine-overview_hr.pdf)

italiano (IT) (136.16 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/it/documents/overview/fycompa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (178.33 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/lv/documents/overview/fycompa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (158.81 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/lt/documents/overview/fycompa-epar-medicine-overview_lt.pdf)

magyar (HU) (158.9 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/hu/documents/overview/fycompa-epar-medicine-overview_hu.pdf)

Malti (MT) (169.67 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/mt/documents/overview/fycompa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (137.31 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/nl/documents/overview/fycompa-epar-medicine-overview_nl.pdf)

polski (PL) (160.03 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/pl/documents/overview/fycompa-epar-medicine-overview_pl.pdf)

português (PT) (137.56 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/pt/documents/overview/fycompa-epar-medicine-overview_pt.pdf)

română (RO) (157.33 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/ro/documents/overview/fycompa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (159.46 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/sk/documents/overview/fycompa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (158.77 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/sl/documents/overview/fycompa-epar-medicine-overview_sl.pdf)

Suomi (FI) (135.12 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/fi/documents/overview/fycompa-epar-medicine-overview_fi.pdf)

svenska (SV) (134.88 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

13/01/2021

[View](/sv/documents/overview/fycompa-epar-medicine-overview_sv.pdf)

Fycompa : EPAR - Risk-management-plan

English (EN) (750.94 KB - PDF)

**First published:** 13/01/2021

**Last updated:** 24/02/2023

[View](/en/documents/rmp/fycompa-epar-risk-management-plan_en.pdf)

## Product information

Fycompa : EPAR - Product Information

English (EN) (735.79 KB - PDF)

**First published:** 07/08/2012

**Last updated:** 10/05/2023

[View](/en/documents/product-information/fycompa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-620)

български (BG) (786.29 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/bg/documents/product-information/fycompa-epar-product-information_bg.pdf)

español (ES) (675.39 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/es/documents/product-information/fycompa-epar-product-information_es.pdf)

čeština (CS) (849.52 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/cs/documents/product-information/fycompa-epar-product-information_cs.pdf)

dansk (DA) (748.52 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/da/documents/product-information/fycompa-epar-product-information_da.pdf)

Deutsch (DE) (869.78 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/de/documents/product-information/fycompa-epar-product-information_de.pdf)

eesti keel (ET) (860.36 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/et/documents/product-information/fycompa-epar-product-information_et.pdf)

ελληνικά (EL) (1.15 MB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/el/documents/product-information/fycompa-epar-product-information_el.pdf)

français (FR) (865.04 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/fr/documents/product-information/fycompa-epar-product-information_fr.pdf)

hrvatski (HR) (777.89 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/hr/documents/product-information/fycompa-epar-product-information_hr.pdf)

íslenska (IS) (683.88 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/is/documents/product-information/fycompa-epar-product-information_is.pdf)

italiano (IT) (615.37 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/it/documents/product-information/fycompa-epar-product-information_it.pdf)

latviešu valoda (LV) (897.37 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/lv/documents/product-information/fycompa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (703.36 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/lt/documents/product-information/fycompa-epar-product-information_lt.pdf)

magyar (HU) (767.09 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/hu/documents/product-information/fycompa-epar-product-information_hu.pdf)

Malti (MT) (909.32 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/mt/documents/product-information/fycompa-epar-product-information_mt.pdf)

Nederlands (NL) (836.2 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/nl/documents/product-information/fycompa-epar-product-information_nl.pdf)

norsk (NO) (756.07 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/no/documents/product-information/fycompa-epar-product-information_no.pdf)

polski (PL) (889.05 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/pl/documents/product-information/fycompa-epar-product-information_pl.pdf)

português (PT) (792.21 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/pt/documents/product-information/fycompa-epar-product-information_pt.pdf)

română (RO) (1013.66 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/ro/documents/product-information/fycompa-epar-product-information_ro.pdf)

slovenčina (SK) (885.51 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/sk/documents/product-information/fycompa-epar-product-information_sk.pdf)

slovenščina (SL) (832.16 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/sl/documents/product-information/fycompa-epar-product-information_sl.pdf)

Suomi (FI) (784.99 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/fi/documents/product-information/fycompa-epar-product-information_fi.pdf)

svenska (SV) (757.59 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

10/05/2023

[View](/sv/documents/product-information/fycompa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00009255/202207 27/04/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fycompa : EPAR - All Authorised presentations

English (EN) (27.88 KB - PDF)

**First published:** 07/08/2012

**Last updated:** 29/09/2016

[View](/en/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-278)

български (BG) (49.79 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/bg/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_bg.pdf)

español (ES) (33.91 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/es/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (43.16 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/cs/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (28.79 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/da/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.12 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/de/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (36.37 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/et/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.79 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/el/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_el.pdf)

français (FR) (31.07 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/fr/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.96 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/hr/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.19 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/is/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (32.82 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/it/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.58 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/lv/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (53.54 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/lt/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (43.09 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/hu/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (87.23 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/mt/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.58 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/nl/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.39 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/no/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_no.pdf)

polski (PL) (43.13 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/pl/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_pl.pdf)

português (PT) (29.11 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/pt/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.42 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/ro/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.07 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/sk/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.31 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/sl/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.91 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/fi/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.69 KB - PDF)

**First published:**

07/08/2012

**Last updated:**

29/09/2016

[View](/sv/documents/all-authorised-presentations/fycompa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fycompa Active substance perampanel International non-proprietary name (INN) or common name perampanel Therapeutic area (MeSH) Epilepsies, Partial Anatomical therapeutic chemical (ATC) code N03AX22

### Pharmacotherapeutic group

- Antiepileptics
- Other antiepileptics

### Therapeutic indication

Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.

Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

## Authorisation details

EMA product number EMEA/H/C/002434 Marketing authorisation holder

Eisai GmbH

Edmund-Rumpler-Straße 3

Opinion adopted 24/05/2012 Marketing authorisation issued 23/07/2012 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fycompa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (227.29 KB - PDF)

**First published:** 17/10/2012

**Last updated:** 10/05/2023

[View](/en/documents/procedural-steps-after/fycompa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Fycompa-H-C-002434-P46-027 : EPAR - Assessment Report

Adopted

Reference Number: EMA/483426/2023

English (EN) (2.04 MB - PDF)

**First published:** 31/10/2023

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-027-epar-assessment-report_en.pdf)

Fycompa-H-C-PSUSA-00009255-202207 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/151418/2023

English (EN) (144.98 KB - PDF)

**First published:** 10/05/2023

[View](/en/documents/scientific-conclusion/fycompa-h-c-psusa-00009255-202207-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Fycompa-H-C-002434-P46-025 : EPAR - Assessment Report

Adopted

Reference Number: EMA/79794/2023

English (EN) (2.28 MB - PDF)

**First published:** 22/02/2023

**Last updated:** 22/02/2023

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-025-epar-assessment-report_en.pdf)

Fycompa-H-C-002434-P46-024 : EPAR - Assessment Report

Adopted

Reference Number: EMA/736888/2022

English (EN) (1.12 MB - PDF)

**First published:** 13/10/2022

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-024-epar-assessment-report_en.pdf)

Fycompa-H-C-PSUSA-00009255-202107: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/248596/2022

English (EN) (139.79 KB - PDF)

**First published:** 05/07/2022

[View](/en/documents/scientific-conclusion/fycompa-h-c-psusa-00009255-202107-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Fycompa-H-C-002434-P46-020: EPAR - Assessment report

Adopted

Reference Number: EMA/437972/2021

English (EN) (1.16 MB - PDF)

**First published:** 22/09/2021

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-020-epar-assessment-report_en.pdf)

Fycompa-H-C-002434-P46-019 : EPAR - Assessment report

Adopted

Reference Number: EMA/114809/2021

English (EN) (1.55 MB - PDF)

**First published:** 12/05/2021

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-019-epar-assessment-report_en.pdf)

Fycompa-H-C-PSUSA-00009255-202007: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/256140/2021

English (EN) (98.27 KB - PDF)

**First published:** 07/05/2021

[View](/en/documents/scientific-conclusion/fycompa-h-c-psusa-00009255-202007-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Fycompa-H-C-2434-II-0047 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/695418/2020

English (EN) (3.81 MB - PDF)

**First published:** 13/01/2021

[View](/en/documents/variation-report/fycompa-h-c-2434-ii-0047-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Fycompa (II-47)

Adopted

Reference Number: EMA/CHMP/471522/2020

English (EN) (141.66 KB - PDF)

**First published:** 18/09/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fycompa-ii-47_en.pdf)

Fycompa-H-C-PSUSA-00009255-201907 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/165665/2020

English (EN) (124.9 KB - PDF)

**First published:** 27/05/2020

[View](/en/documents/scientific-conclusion/fycompa-h-c-psusa-00009255-201907-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Fycompa-H-C-002434-P46-0017 : EPAR - Assessment Report

Adopted

Reference Number: EMA/16999/2019

English (EN) (452 KB - PDF)

**First published:** 21/02/2020

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-0017-epar-assessment-report_en.pdf)

Fycompa-H-C-002434-P46-0016 : EPAR - Assessment Report

Adopted

Reference Number: EME/340381/2017

English (EN) (370.46 KB - PDF)

**First published:** 17/08/2017

**Last updated:** 17/08/2017

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-0016-epar-assessment-report_en.pdf)

Fycompa-H-C-002434-P46-0014 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/733238/2015

English (EN) (636.35 KB - PDF)

**First published:** 09/11/2015

**Last updated:** 09/11/2015

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-0014-epar-assessment-report_en.pdf)

Fycompa-H-C-002434-P46-012.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/732770/2015

English (EN) (2.04 MB - PDF)

**First published:** 09/11/2015

**Last updated:** 09/11/2015

[View](/en/documents/variation-report/fycompa-h-c-002434-p46-0121-epar-assessment-report_en.pdf)

Fycompa-H-C-2434-II-0016 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/518002/2015

English (EN) (9.99 MB - PDF)

**First published:** 03/08/2015

**Last updated:** 03/08/2015

[View](/en/documents/variation-report/fycompa-h-c-2434-ii-0016-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Fycompa

Adopted

Reference Number: EMA/CHMP/324690/2015

English (EN) (67.06 KB - PDF)

**First published:** 22/05/2015

**Last updated:** 22/05/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fycompa_en.pdf)

Fycompa-H-C-2434-PSUV-0009 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/764026/2013

English (EN) (52.85 KB - PDF)

**First published:** 11/12/2013

**Last updated:** 11/12/2013

[View](/en/documents/scientific-conclusion/fycompa-h-c-2434-psuv-0009-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Fycompa : EPAR - Public assessment report

Adopted

Reference Number: EMA/424476/2012

English (EN) (2.29 MB - PDF)

**First published:** 07/08/2012

**Last updated:** 07/08/2012

[View](/en/documents/assessment-report/fycompa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fycompa

Adopted

Reference Number: EMA/CHMP/242764/2012

English (EN) (71.89 KB - PDF)

**First published:** 25/05/2012

**Last updated:** 25/05/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fycompa_en.pdf)

#### News on Fycompa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2015) 22/05/2015

#### More information on Fycompa

- [EMEA-000467-PIP01-08-M15 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000467-pip01-08-m15)
- [An Open-Label, Observational, Prospective, Multicenter Study to Evaluate the Long-Term Efficacy and Safety of Perampanel as Monotherapy in Subjects Age 4 Years and Older with Focal Onset Seizures: PORTABLE Study - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000572)
- [A global postmarketing observational safety study to evaluate the safety and tolerability of Fycompa (perampanel) as add-on therapy in epilepsy patients aged &gt; 12 years - post-authorisation study](https://catalogues.ema.europa.eu/study/38590)
- [A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects &gt;=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy - post-authorisation study](https://catalogues.ema.europa.eu/study/105877)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 31/10/2023

## Share this page

[Back to top](#main-content)